PHARMACEUTICAL COMPOSITION COMPRISING TPO OR AN AGONIST OF THE TPO RECEPTOR
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Feb 20, 2014
app pub date -
Aug 17, 2012
filing date -
Aug 17, 2012
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to a new use of TPO or a TPO/mpl receptor agonist as an adjuvant of a treatment of a neoplastic disease by irradiation or chemotherapeutic agents in order to prevent genomic instability of hematopoietic stem cells incurred through radio- or chemotherapy and hence to prevent the occurrence of secondary cancers, namely acute myelogenous leukemia and myelodisplasia.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully